An Open-Label, Nonrandomized, Crossover Study to Evaluate the Potential Effect of Multiple Doses of Neratinib on the Pharmacokinetics of a Single Dose of Digoxin When Administered Orally to Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 May 2012
At a glance
- Drugs Digoxin; Neratinib
- Indications Atrial fibrillation; Atrial flutter; Breast cancer; Heart failure; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 May 2012 Actual patient number is 27 according to ClinicalTrials.gov.
- 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
- 28 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.